Mentions
Extended reach
Total likes
Video views
AI synopsis
The social discussions consistently praise the trial's promising outcomes with phrases like 'significantly reduces risk' and 'impressive effects,' illustrating both excitement and recognition of its potential impact; words such as 'benefits' and 'powerful' further reinforce the high interest and perceived importance of the findings.
Most discussions support the positive findings of the EMPA-KIDNEY trial, emphasizing its efficacy in reducing kidney disease progression and cardiovascular risks.
The widespread sharing of trial results, detailed analyses, and references to related studies indicates high curiosity and focus on recent advancements.
Several discussions dive into specifics like subgroup analyses, study design, and long-term effects, showing deep engagement with the research.
The discussions highlight how the trial’s results could influence clinical practice globally, demonstrating significant impacts on treatment approaches for CKD.
Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVvVg7V37b Editorial: Another Win for SGLT2 Inhibitors in Chronic Kidney Disease https://t.co/d3RO3XwHIu #Nephrology https://t.co/uDimwYVJiU
Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes https://t.co/6GTJoq4nNV https://t.co/iVhcJAUQ89
Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t.co/AUhn7VXl4s https://t.co/31hRD1YfUv
Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KIDNEY https://t.co/7PIWHc8Ame https://t.co/cjUES79CV7
EMPA-Kidney: Empagliflozin in Patients with Chronic Kidney Disease. It works, now keep using it ! @NEJM https://t.co/GmDgfkgPix
2. Empagliflozin in Patients with Chronic Kidney Disease https://t.co/HFgzPgrRFx #nephrology https://t.co/gxu5lgS2Py
Explore the latest advancements in kidney care from American Kidney Week 2024, highlighting new medications, dialysis technologies, and stem cell research aimed at reducing proteinuria and improving kidney function.
Prof Dr Dr Thimoteus Speer discusses the role of inflammatory signaling pathways in the high cardiovascular risk among CKD patients and explores how IL6 inhibition with Ziltivekimab, currently under investigation in the…
This video discusses the EMPA-KIDNEY trial which explores how empagliflozin affects patients with chronic kidney disease. The study shows a reduced rate of disease progression and hospitalizations in patients treated…
Prof. van der Giet, Prof. Chenot, and Prof. Kuhlmann discuss the interdisciplinary outpatient care of chronic kidney disease (CKD) patients, focusing on S3 guidelines for managing patients not requiring kidney…
Dr. Herrington, Dr. Donovan, Dr. Grabner, and Dr. Edmonston discuss whether the hormone FGF23 contributes to cardiovascular disease, based on recent Mendelian Randomization data and experimental studies, highlighting…
The EMPA-KIDNEY study explores empagliflozin's impact on CKD progression and cardiovascular outcomes, showing reduced disease progression and hospitalizations in patients at risk.
In this episode, Koyal and Kenar recap essential knowledge about IgA nephropathy (IgAN) for board examinations and treatment decisions. Emphasizing a recent study, they reveal that methylprednisolone reduces serious…
This week, we delve into the critical findings regarding cardiac troponin I levels. A recent study reveals a significant correlation between elevated troponin levels post-surgery and increased 30-day mortality…
In this podcast, John Mandrola MD discusses SGLT2 inhibitors, their effects on chronic kidney disease, and highlights significant trial outcomes showing a 30% lower risk of severe kidney issues with Canagliflozin. A…
The second part of our 2025 internist annual review presents the top nephrology and hypertensiology studies of 2025, featuring experts from across Europe discussing recent developments and key clinical trials.
医師から問い合わせがあったこともあり、今回の実習生との論文抄読会(RCT編)はEMPA-KIDNEY試験にしました。 Empagliflozin in Patients with Chronic Kidney Disease https://t.co/uviJyZi2ct
RT @drbennisahmed: Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary anal…
RT @drbennisahmed: Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary anal…
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of https://t.co/89Xj2q1HiL
RT @gunnar_heine: Elke Schäffner @NDTsocial and @MarkusAtHome https://t.co/Ja1NopCz9r Diagnosing & treating CKD in elder pat
RT @gunnar_heine: @sijiezheng @DanEdmonston @MarkusAtHome Sorry, I only hava a personal copy. However we hope to meet @DanEdmonston soon @M…
Elke Schäffner @NDTsocial and @MarkusAtHome https://t.co/Ja1NopCz9r Diagnosing & treating CKD in elder pat https://t.co/fuk6cRStfJ
@sijiezheng @DanEdmonston @MarkusAtHome Sorry, I only hava a personal copy. However we hope to meet @DanEdmonston soon @MarkusAtHome The study design is discussed at https://t.co/Ja1NopC1jT
RT @JonathanNefro: Con enfermedad renal crónica G3-4 (con y sin diabetes), Empagliflozina ↓28% el riesgo de progresión y muerte cardiovascu…
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease https://t.co/XFFjzYP0SG
A new study shows that combining finerenone and empagliflozin in patients with chronic kidney disease and type 2 diabetes reduces urine albumin levels more effectively than either drug alone, without unexpected side effects. - Read more: https://t.co/OR65fdqKuN
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
RT @drbennisahmed: Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for dise…
Empagliflozin in Patients with CKD Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes https://t.co/6GTJoq4nNV https://t.co/iVhcJAUQ89
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @drbennisahmed: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at ri…
RT @drbennisahmed: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at ri…
RT @drbennisahmed: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at ri…
RT @drbennisahmed: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at ris…
RT @drbennisahmed: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at ri…
EMPA-KIDNEY: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease
RT @drbennisahmed: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at ri…
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at risk for progression, empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued https://t.co/R9Flkl35DV https://t.co/sTutQbHnid
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at risk for progression, empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued https://t.co/R9Flkl35DV https://t.co/d686MtyTKQ
Impact of primary #kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial https://t.co/a1SV2n2YFg #CKD #OpenAccess #WorldKidneyDay
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease | New England Journal of Medicine https://t.co/PR5rv7shgo
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease | New England Journal of Medicine https://t.co/MNH3hrnFmm
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @drbennisahmed: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at ri…
RT @drbennisahmed: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at ri…
RT @drbennisahmed: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at ri…
RT @lconcepcionmd: Follow up of the EMPA kidney trial:Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease | New Engl…
RT @drbennisahmed: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at ri…
Follow up of the EMPA kidney trial:Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease | New England Journal of Medicine https://t.co/tMYqztzG3g
RT @drbennisahmed: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at ri…
RT @drbennisahmed: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at ri…
RT @drbennisahmed: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at ri…
RT @drbennisahmed: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at ri…
RT @drbennisahmed: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at ri…
RT @drbennisahmed: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at ri…
RT @drbennisahmed: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at ri…
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at risk for progression, empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued. https://t.co/R9Flkl35DV https://t.co/IL9BNC7Dfq
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @antithrombosis: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease | New England Journal of Medicine https://t.…
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease | New England Journal of Medicine https://t.co/QIvdqPb4xZ
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease | New England Journal of Medicine https://t.co/DczfmbMLoq
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease In a broad range of patients with CKD at risk for progression, empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued https://t.co/R9Flkl35DV https://t.co/ixYJJ6eGra
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
RT @NEJM: Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVv…
Original Article: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY trial) https://t.co/yVvVg7V37b Editorial: Another Win for SGLT2 Inhibitors in Chronic Kidney Disease https://t.co/d3RO3XwHIu #Nephrology https://t.co/uDimwYVJiU
RT @collazor1: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease | New England Journal of Medicine https://t.co/aG…
RT @collazor1: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease | New England Journal of Medicine https://t.co/aG…
RT @collazor1: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease | New England Journal of Medicine https://t.co/aG…
RT @collazor1: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease | New England Journal of Medicine https://t.co/aG…
RT @collazor1: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease | New England Journal of Medicine https://t.co/aG…
RT @collazor1: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease | New England Journal of Medicine https://t.co/aG…
RT @collazor1: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease | New England Journal of Medicine https://t.co/aG…
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease | New England Journal of Medicine https://t.co/Y4iBr2pOha
RT @KSusztak: Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease | @NEJM https://t.co/wSihhLIhll
“Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.” Publié ce jour dans le @nejm.org. #Medsky #NephroSky #EMPA-KIDNEY #CKD www.nejm.org/doi/full/10....
@VPrasadMDMPH @djc795 @JAMANetworkOpen @drjohnm @AndrewFoy82 Fair point. FWIW this ongoing discussion has spurred all current trial programs that I am aware of in HF and CKD to collect and report all-cause hospitalizations. Some like EMPA-KIDNEY have elevated all-cause hospitalization to a key secondary endpoint https://t.co/lOU8CxQCpW
RT @NephJC: T0c: The primary aim of the original EMPA-KIDNEY? To assess if empagliflozin delays CKD progression or reduces CV mortality. Di…
T0c: The primary aim of the original EMPA-KIDNEY? To assess if empagliflozin delays CKD progression or reduces CV mortality. Dive into the details of this crucial trial. #NephJC https://t.co/q2A6k9H72T
T0c: The primary aim of the original EMPA-KIDNEY? To assess if empagliflozin delays CKD progression or reduces CV mortality. Dive into the details of this crucial trial. #NephJC https://t.co/q2A6k9HESr
RT @javier20ch: Empaglifozina en pacientes con ERC (EMPA-KIDNEY).
EMPA KIDNEYで末期腎不全(維持透析 or 移植)が各群約3300人で、108 vs 158。(Table S5) 観察期間が3年なので、100人年あたり1人くらいは末期腎不全になっている。 台湾人が腎不全になりにくいのか。 それともICD-10codeや処置で透析を抽出すると漏れるのか、なぜだろう。 https://t.co/dyNbipm5iK
Empagliflozin in Patients with Chronic Kidney Disease | New England Journal of Medicine https://t.co/q8QYH3bBdS
24a) @goKIDIGO 3.7 Sodium-glucose cotransporter-2 inhibitors (#SGLT2i) Some of the trials that support the use of SGLT2i in this population are: #CREDENCE
24a) @goKIDIGO 3.7 Sodium-glucose cotransporter-2 inhibitors (#SGLT2i) Some of the trials that support the use of SGLT2i in this population are: #CREDENCE
日本 vs 日本以外というよりベースのアルブミン尿の違いによる違い？？ https://t.co/RyQF51a9jF https://t.co/tMEB3jhPuz
Empagliflozin in Patients with Chronic Kidney Disease | NEJM https://t.co/VKgOuCZ8aP
@kaitlyn_mcsurdy ISCHEMIA https://t.co/tXaQ0GcA4d PEN-FAST https://t.co/Ea57hKTk2n EMPA-KIDNEY https://t.co/iwwARGuQif
Empagliflozin in Patients with Chronic Kidney Disease-EMPA-KIDNEY trial The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression were assessed. January 12, 2023 https://t.co/ciqFchG6Q0 https://t.co/c2fZavOWJK
RT @Jwaitz: @EBMTeacher @kidney_boy @edgarvlermamd @medrants EMPA-KIDNEY: flozins for everyone https://t.co/W4sigQnFhb
@EBMTeacher @kidney_boy @edgarvlermamd @medrants EMPA-KIDNEY: flozins for everyone https://t.co/W4sigQnFhb
RT @ValleAlfonso: #CaReMe
@CaptainKidney79 @brendonneuen @SWadhwaniMD @Proximal_Baxi @BryceBarr9 @ChristosArgyrop @cavanaugh_do @DanaRizk1 @SeanJBarbour @Jwaitz @jordy_bc @kidney_boy @IgAN_JBarratt @BradRovin @kidneybiz I think it was an amendment - scroll down further to page 69 to final version (One before is 10 mg, you are right) https://t.co/QIOJkGDBWZ https://t.co/u6oGdnLoSj
Among 6609 patients with CKD, were randomly assigned to #Empagliflozin vs Placebo, Empagliflozin patients were significantly 28% less likely to primary outcomes compared to placebo. Notably the beneficial effect in subgroup.| EMPA-KIDNEY trial https://t.co/GKjL7qZ85c https://t.co/wHIqYJPTlY
@Doshe_chan تفضلي https://t.co/RtCOgBrWBi
15/ For more details on the data, check out the links below:
RT @JuanPayanLopez1: Ya está el empakidney , con una N de casi 7000, más del 30% con FG 20-30ml/min y casi el 50% con alb/cr < 300 mg/g. ht…
Empagliflozin in Patients with Chronic Kidney Disease | NEJM https://t.co/dlvvMZx5Ca
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @NEJM: 2. Empagliflozin in Patients with Chronic Kidney Disease https://t.co/HFgzPgrRFx #nephrology https://t.co/gxu5lgS2Py
RT @NEJM: 2. Empagliflozin in Patients with Chronic Kidney Disease https://t.co/HFgzPgrRFx #nephrology https://t.co/gxu5lgS2Py
RT @NEJM: 2. Empagliflozin in Patients with Chronic Kidney Disease https://t.co/HFgzPgrRFx #nephrology https://t.co/gxu5lgS2Py
2. Empagliflozin in Patients with Chronic Kidney Disease https://t.co/HFgzPgrRFx #nephrology https://t.co/gxu5lgS2Py
RT @edgarvlermamd: EMPA-KIDNEY: Among a wide range of patients w/ CKD who were at risk for disease progression, empagliflozin therapy led t…
RT @edgarvlermamd: EMPA-KIDNEY: Among a wide range of patients w/ CKD who were at risk for disease progression, empagliflozin therapy led t…
RT @edgarvlermamd: EMPA-KIDNEY: Among a wide range of patients w/ CKD who were at risk for disease progression, empagliflozin therapy led t…
RT @edgarvlermamd: EMPA-KIDNEY: Among a wide range of patients w/ CKD who were at risk for disease progression, empagliflozin therapy led t…
RT @edgarvlermamd: EMPA-KIDNEY: Among a wide range of patients w/ CKD who were at risk for disease progression, empagliflozin therapy led t…
RT @edgarvlermamd: EMPA-KIDNEY: Among a wide range of patients w/ CKD who were at risk for disease progression, empagliflozin therapy led t…
@tripnephro https://t.co/hdblaPi1Gt これじゃね？
@pabonnet @FaconFlorian @exercer_Revue J'ai pas trop insisté sur le blog c'est vrai : https://t.co/IaSh29MHx3 pour la dapa et https://t.co/lFciA4MLTa pour l empa. Avantage à la dapa qui réduit en plus des évènements rénaux, les événements CV et la mortalité
علم بخونیم یکم https://t.co/KoL6E5t03T
Another blockbuster UK-based trial - it's @willkidney with EMPA-KIDNEY! #UKKW2023 https://t.co/lBIYk86ZWo
@rendzborg_ Not even just HF https://t.co/bGGCSdtyw6
RT @cardiomet_CE: 19f) #EMPA_KIDNEY (earn more credit, learn more at https://t.co/OjfKn6alDY)
19f) #EMPA_KIDNEY (earn more credit, learn more at https://t.co/OjfKn6alDY)
RT @ckd_ce: 19f) #EMPA_KIDNEY (earn more credit, learn more at https://t.co/7Q90SSXQ8X)
19f) #EMPA_KIDNEY (earn more credit, learn more at https://t.co/7Q90SSXQ8X)
Ending P4 year with my last journal club - discussing the EMPA-KIDNEY study (empagliflozin in pts with CKD). Promising results?
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…
RT @cfaul1: Does FGF-23 Induce Cardiovascular Disease? - Dr. Donovan, Dr. Herrington... https://t.co/k45nm4cubv via @YouTube
RT @edgarvlermamd: .@Brian_rifkin made it to #NKFClinicals with this #VisualAbstract of EMPA-KIDNEY #Nephpearls #NephJC
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…
RT @gunnar_heine: Now online: CID-MBD's fantastic four on "Does FGF-23 Induce Cardiovascular Disease?" https://t.co/leA4p175Ho via @YouTube
Does FGF-23 Induce Cardiovascular Disease? - Dr. Donovan, Dr. Herrington... https://t.co/k45nm4cubv via @YouTube
RT @gunnar_heine: Does FGF-23 Induce Cardiovascular Disease? 4 Global Experts @willkidney @KillianDonovan @Ascclepios @DanEdmonston 3 Med…
Now online: CID-MBD's fantastic four on "Does FGF-23 Induce Cardiovascular Disease?" https://t.co/leA4p175Ho via @YouTube
RT @gunnar_heine: Does FGF-23 Induce Cardiovascular Disease? 4 Global Experts @willkidney @KillianDonovan @Ascclepios @DanEdmonston 3 Med…
RT @gunnar_heine: Does FGF-23 Induce Cardiovascular Disease? 4 Global Experts @willkidney @KillianDonovan @Ascclepios @DanEdmonston 3 Med…
RT @gunnar_heine: Does FGF-23 Induce Cardiovascular Disease? 4 Global Experts @willkidney @KillianDonovan @Ascclepios @DanEdmonston 3 Med…
RT @gunnar_heine: Does FGF-23 Induce Cardiovascular Disease? 4 Global Experts @willkidney @KillianDonovan @Ascclepios @DanEdmonston 3 Med…
Does FGF-23 Induce Cardiovascular Disease? 4 Global Experts @willkidney @KillianDonovan @Ascclepios @DanEdmonston 3 Medical Societies @com_SFNDT @oegn @dgfn_ev 2 Opinions 1 Night before Streaming Tomorrow at MARKUS@HOMe https://t.co/leA4p175Ho via @YouTube with @MarcusSaemann
RT @cardiomet_CE: 17) Most pts w/#T2D & #CKD have improved rates of #ESRD #MACE #CV death & #HF hospitalization w/#SGLT2i after maximizing…
17) Most pts w/#T2D & #CKD have improved rates of #ESRD #MACE #CV death & #HF hospitalization w/#SGLT2i after maximizing #ACEI/#ARB dose. In some trials, greatest benefit has been observed for pts with the highest UAE (#CREDENCE #EMPA_KIDNEY, below)…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…
https://t.co/gEoYzQ9M5y
RT @edgarvlermamd: .@Brian_rifkin made it to #NKFClinicals with this #VisualAbstract of EMPA-KIDNEY #Nephpearls #NephJC
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…
Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KIDNEY https://t.co/7PIWHc8Ame https://t.co/cjUES79CV7
.@Brian_rifkin made it to #NKFClinicals with this #VisualAbstract of EMPA-KIDNEY #Nephpearls #NephJC
17) Most pts w/#T2D & #CKD have improved rates of #ESRD #MACE #CV death & #HF hospitalization w/#SGLT2i after maximizing #ACEI/#ARB dose. In some trials, greatest benefit has been observed for pts with the highest UAE (#CREDENCE #EMPA_KIDNEY, below)…
Discussion of empagliflozin and 2023 EMPA-KIDNEY https://t.co/KWvBZ2R6CJ and DELIVER trials https://t.co/aPU2w9Ojax https://t.co/uPHGnJtMlR
RT @Ironken6: Late breaking clinical trial DETERMINANTS OF THE EFFECTS OF SGLT2I ON PROGRESSION OF CKD: FURTHER RESULTS FROM THE EMPA-KIDNE…
RT @Ironken6: Late breaking clinical trial DETERMINANTS OF THE EFFECTS OF SGLT2I ON PROGRESSION OF CKD: FURTHER RESULTS FROM THE EMPA-KIDNE…
RT @Ironken6: Late breaking clinical trial DETERMINANTS OF THE EFFECTS OF SGLT2I ON PROGRESSION OF CKD: FURTHER RESULTS FROM THE EMPA-KIDNE…
RT @Ironken6: Late breaking clinical trial DETERMINANTS OF THE EFFECTS OF SGLT2I ON PROGRESSION OF CKD: FURTHER RESULTS FROM THE EMPA-KIDNE…
RT @Ironken6: Late breaking clinical trial DETERMINANTS OF THE EFFECTS OF SGLT2I ON PROGRESSION OF CKD: FURTHER RESULTS FROM THE EMPA-KIDNE…
RT @Ironken6: Late breaking clinical trial DETERMINANTS OF THE EFFECTS OF SGLT2I ON PROGRESSION OF CKD: FURTHER RESULTS FROM THE EMPA-KIDNE…
RT @Ironken6: Late breaking clinical trial DETERMINANTS OF THE EFFECTS OF SGLT2I ON PROGRESSION OF CKD: FURTHER RESULTS FROM THE EMPA-KIDNE…
RT @Ironken6: Late breaking clinical trial DETERMINANTS OF THE EFFECTS OF SGLT2I ON PROGRESSION OF CKD: FURTHER RESULTS FROM THE EMPA-KIDNE…
Late breaking clinical trial DETERMINANTS OF THE EFFECTS OF SGLT2I ON PROGRESSION OF CKD: FURTHER RESULTS FROM THE EMPA-KIDNEY TRIAL @NatalieStaplin Further reading : https://t.co/fTLxGb49Mv #ISNWCN @ISNWCN @ISNeducation @ISNkidneycare
EMPA-KIDNEY (fase III) El riesgo de progresión de la enfermedad renal o de muerte por causas CV se redujo significativamente en un 28% frente al placebo (CRI;0,72; IC del 95% 0,64 a 0,82; P<0,000001) https://t.co/hiOSAHpnuO https://t.co/WoxD2Xix7T
27) #EMPA_KIDNEY included patients with eGFR as low as 20 mL/min with no #UACR cutoff. 46% had #T2D. #Empagliflozin ⬇️progression of kidney disease or #CV death and was also consistent across subgroups.
RT @GRUPOCRONOSSEF1:
Los iSGLT2 también proporcionan protección renal. La Empagliflozina reduce los eventos de empeoramiento de función o complicaciones renales en pacientes con ERC hasta FG basales de 20ml/min #ClavesIC #eCardio23 EMPA-KIDNEY group https://t.co/KAxp9zuARh https://t.co/DbZidFezqt
At @senjoven Lab @DrMontomoli will explains us EMPA-KIDNEY results… here an appetizer
RT @gunnar_heine: Freitag 19:15 (und danach "on demand"): Unsere zweite online Nierenbiopsiekonferenz mit Prof. Kerstin Amann (Erlangen) un…
RT @MondaEmanuele: Empagliflozin in Patients with Chronic Kidney Disease @NEJM https://t.co/Ayp91FoQYv https://t.co/AMgyccdpKv
RT @gunnar_heine: Freitag 19:15 (und danach "on demand"): Unsere zweite online Nierenbiopsiekonferenz mit Prof. Kerstin Amann (Erlangen) un…
RT @gunnar_heine: Freitag 19:15 (und danach "on demand"): Unsere zweite online Nierenbiopsiekonferenz mit Prof. Kerstin Amann (Erlangen) un…
RT @gunnar_heine: Freitag 19:15 (und danach "on demand"): Unsere zweite online Nierenbiopsiekonferenz mit Prof. Kerstin Amann (Erlangen) un…
Freitag 19:15 (und danach "on demand"): Unsere zweite online Nierenbiopsiekonferenz mit Prof. Kerstin Amann (Erlangen) und Prof. Kirsten de Groot (Offenbach) https://t.co/eiuai8Z9BF via @YouTube Wissenschaftliche Partner @oegnephro @com_SFNDT @dgfn_ev
RT @MondaEmanuele: Empagliflozin in Patients with Chronic Kidney Disease @NEJM https://t.co/Ayp91FoQYv https://t.co/AMgyccdpKv
RT @MondaEmanuele: Empagliflozin in Patients with Chronic Kidney Disease @NEJM https://t.co/Ayp91FoQYv https://t.co/AMgyccdpKv
RT @MondaEmanuele: Empagliflozin in Patients with Chronic Kidney Disease @NEJM https://t.co/Ayp91FoQYv https://t.co/AMgyccdpKv
#PublicaSalutIB Ús de l'empagliflozina en pacients amb malaltia renal crònica https://t.co/f9wv8UWgih @SonEspases @idisbaib https://t.co/hQEGCMBeof https://t.co/82KKCjQhaA
RT @MondaEmanuele: Empagliflozin in Patients with Chronic Kidney Disease @NEJM https://t.co/Ayp91FoQYv https://t.co/AMgyccdpKv
RT @MondaEmanuele: Empagliflozin in Patients with Chronic Kidney Disease @NEJM https://t.co/Ayp91FoQYv https://t.co/AMgyccdpKv
RT @MondaEmanuele: Empagliflozin in Patients with Chronic Kidney Disease @NEJM https://t.co/Ayp91FoQYv https://t.co/AMgyccdpKv
RT @MondaEmanuele: Empagliflozin in Patients with Chronic Kidney Disease @NEJM https://t.co/Ayp91FoQYv https://t.co/AMgyccdpKv
RT @MondaEmanuele: Empagliflozin in Patients with Chronic Kidney Disease @NEJM https://t.co/Ayp91FoQYv https://t.co/AMgyccdpKv
RT @MondaEmanuele: Empagliflozin in Patients with Chronic Kidney Disease @NEJM https://t.co/Ayp91FoQYv https://t.co/AMgyccdpKv
RT @MondaEmanuele: Empagliflozin in Patients with Chronic Kidney Disease @NEJM https://t.co/Ayp91FoQYv https://t.co/AMgyccdpKv
RT @MondaEmanuele: Empagliflozin in Patients with Chronic Kidney Disease @NEJM https://t.co/Ayp91FoQYv https://t.co/AMgyccdpKv
RT @MondaEmanuele: Empagliflozin in Patients with Chronic Kidney Disease @NEJM https://t.co/Ayp91FoQYv https://t.co/AMgyccdpKv
RT @MondaEmanuele: Empagliflozin in Patients with Chronic Kidney Disease @NEJM https://t.co/Ayp91FoQYv https://t.co/AMgyccdpKv
RT @MondaEmanuele: Empagliflozin in Patients with Chronic Kidney Disease @NEJM https://t.co/Ayp91FoQYv https://t.co/AMgyccdpKv
RT @MondaEmanuele: Empagliflozin in Patients with Chronic Kidney Disease @NEJM https://t.co/Ayp91FoQYv https://t.co/AMgyccdpKv
RT @MondaEmanuele: Empagliflozin in Patients with Chronic Kidney Disease @NEJM https://t.co/Ayp91FoQYv https://t.co/AMgyccdpKv
29) SGLT2 Inhibitor EMPA-KIDNEY: showed benefits in pts eGFR < 90 ml/min, but less so in the group with < 300 mg/g proteinuria at 2-years. May be appropriate first-line for CKD 1-2 with #UACR > 1000 mg/g and high risk of rapid declining eGFR. See
#PublicaSalutIB Uso de empagliflozina en pacientes con enfermedad renal crónica https://t.co/FRgP733yMO @SonEspases @idisbaib https://t.co/SFWQy18xTv https://t.co/BKgRqZpD6g
RT @infosalut: #PublicaSalutIB Ús de l'empagliflozina en pacients amb malaltia renal crònica https://t.co/A7zDglXjPo @SonEspases @idisbaib…
#PublicaSalutIB Ús de l'empagliflozina en pacients amb malaltia renal crònica https://t.co/A7zDglXjPo @SonEspases @idisbaib https://t.co/SFWQy18xTv https://t.co/9oMFriM32l
RT @KSusztak: EMPA-Kidney: Empagliflozin in Patients with Chronic Kidney Disease. It works, now keep using it ! @NEJM https://t.co/GmDgfkg…
RT @KSusztak: EMPA-Kidney: Empagliflozin in Patients with Chronic Kidney Disease. It works, now keep using it ! @NEJM https://t.co/GmDgfkg…
RT @KSusztak: EMPA-Kidney: Empagliflozin in Patients with Chronic Kidney Disease. It works, now keep using it ! @NEJM https://t.co/GmDgfkg…
RT @KSusztak: EMPA-Kidney: Empagliflozin in Patients with Chronic Kidney Disease. It works, now keep using it ! @NEJM https://t.co/GmDgfkg…
RT @KSusztak: EMPA-Kidney: Empagliflozin in Patients with Chronic Kidney Disease. It works, now keep using it ! @NEJM https://t.co/GmDgfkg…
RT @KSusztak: EMPA-Kidney: Empagliflozin in Patients with Chronic Kidney Disease. It works, now keep using it ! @NEJM https://t.co/GmDgfkg…
RT @KSusztak: EMPA-Kidney: Empagliflozin in Patients with Chronic Kidney Disease. It works, now keep using it ! @NEJM https://t.co/GmDgfkg…
RT @KSusztak: EMPA-Kidney: Empagliflozin in Patients with Chronic Kidney Disease. It works, now keep using it ! @NEJM https://t.co/GmDgfkg…
RT @KSusztak: EMPA-Kidney: Empagliflozin in Patients with Chronic Kidney Disease. It works, now keep using it ! @NEJM https://t.co/GmDgfkg…
RT @KSusztak: EMPA-Kidney: Empagliflozin in Patients with Chronic Kidney Disease. It works, now keep using it ! @NEJM https://t.co/GmDgfkg…
RT @KSusztak: EMPA-Kidney: Empagliflozin in Patients with Chronic Kidney Disease. It works, now keep using it ! @NEJM https://t.co/GmDgfkg…
RT @KSusztak: EMPA-Kidney: Empagliflozin in Patients with Chronic Kidney Disease. It works, now keep using it ! @NEJM https://t.co/GmDgfkg…
EMPA-Kidney: Empagliflozin in Patients with Chronic Kidney Disease. It works, now keep using it ! @NEJM https://t.co/GmDgfkgPix
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
EMPA-KIDNEY 試験 https://t.co/Nng1jkJvbK
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…
Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t.co/AUhn7VXl4s https://t.co/zeO7bzk3Yc
Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t.co/AUhn7VXl4s https://t.co/31hRD1YfUv
29) SGLT2 Inhibitor EMPA-KIDNEY: showed benefits in patients with eGFR < 90 ml/min, tho less so in the group w/ < 300 mg/g proteinuria at 2-years. May be appropriate first-line for CKD 1-2 w/ #UACR > 1000 mg/g & high risk of rapid declining eGFR. See
RT @ISNkidneycare: @willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with…
RT @Dr_mandheling: 先月発表された論文を受けてUpToDateが『蛋白尿（アルブミン尿300mg/日以上または蛋白尿500mg/日以上）を有する非糖尿病性慢性腎臓病患者では、SGLT2阻害薬による治療を推奨する（Grade 1B）』と 本当か？ Empag…
先月発表された論文を受けてUpToDateが『蛋白尿（アルブミン尿300mg/日以上または蛋白尿500mg/日以上）を有する非糖尿病性慢性腎臓病患者では、SGLT2阻害薬による治療を推奨する（Grade 1B）』と 本当か？ Empagliflozin in Patients with Chronic Kidney Disease - PubMed https://t.co/8kgV9gEFhh
RT @ISNkidneycare: @willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with…
RT @ISNkidneycare: @willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with…
RT @ISNkidneycare: @willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with…
@willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with CKD https://t.co/nWe0d8zpT7 ➡️ Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial https://t.co/MhLOEA6aHq ➡️ ISN visual abstract – Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY) https://t.co/coEmLZrqe8
RT @ISNkidneycare: @willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with…
RT @ISNkidneycare: @willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with…
RT @ISNkidneycare: @willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with…
RT @ISNkidneycare: @willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with…
RT @ISNkidneycare: @willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with…
RT @ISNkidneycare: @willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with…
RT @ISNkidneycare: @willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with…
Want to learn more about lowering the risk of progression of kidney disease? Read this paper in in the New England Journal of Medicine. BBI’s Dr. Katherine Tuttle is a co-author. https://t.co/uLryD6r1GR https://t.co/78BMHMzxdO
RT @ISNkidneycare: @willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with…
RT @ISNkidneycare: @willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with…
RT @ISNkidneycare: @willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with…
RT @ISNkidneycare: @willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with…
RT @ISNkidneycare: @willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with…
RT @ISNkidneycare: @willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with…
@willkidney @adeeralevin @MasaomiNangaku @pecoitsfilho @aymwanghkuhk Further reading: ➡️ Empagliflozin in Patients with CKD https://t.co/nWe0d8R0KF ➡️ Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial https://t.co/MhLOEzOziQ ➡️ ISN visual abstract – Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY) https://t.co/PChpWozN76
RT @RosselloXavier: Glad to share my first @NEJM A long & beautiful journey through @colsantpere @CampusClinicUB @CardioSantPau @HatterCar…
RT @RevistaMFSamfyc: Empagliflozina en pacientes con enfermedad renal crónica https://t.co/kspJWLl4oh PMID 36331190
Empagliflozina en pacientes con enfermedad renal crónica https://t.co/kspJWLl4oh PMID 36331190
RT @redGDPS: Artículo en @PubMedOnline Empagliflozin in Patients with Chronic Kidney Disease https://t.co/0x46UXd0Kl
RT @redGDPS: Full text links @NEJM Empagliflozin in Patients with Chronic Kidney Disease | NEJM https://t.co/KRxCjjKpcu
RT @redGDPS: Artículo en @PubMedOnline Empagliflozin in Patients with Chronic Kidney Disease https://t.co/0x46UXd0Kl
Full text links @NEJM Empagliflozin in Patients with Chronic Kidney Disease | NEJM https://t.co/KRxCjjKpcu
Artículo en @PubMedOnline Empagliflozin in Patients with Chronic Kidney Disease https://t.co/0x46UXd0Kl
2/10 What did I miss? With death, taxes & positive SGLT2i trials being the only certain things in life, why was there still so much excitement last week? Answer: DAPA-CKD recruited down to eGFR 25 & uACR 200mg/g, but EMPA-KIDNEY went even lower on both! https://t.co/q2A6k9HESr
Impressive effect of #SGLT2i in stimulating erythrocytosis. Also impressive effect on pts with #CKD by lowering risk of progression of kidney disease or #cardiovascular #mortality from the EMPA-KIDNEY trial https://t.co/asdSrQDNHQ @Abualfaa https://t.co/75BXNYXIK3
RT @mbotana: Empagliflozin in Patients with Chronic Kidney Disease | NEJM https://t.co/ZokDjvq31b
RT @mbotana: Empagliflozin in Patients with Chronic Kidney Disease | NEJM https://t.co/ZokDjvq31b
RT @mbotana: Empagliflozin in Patients with Chronic Kidney Disease | NEJM https://t.co/ZokDjvq31b
RT @mbotana: Empagliflozin in Patients with Chronic Kidney Disease | NEJM https://t.co/ZokDjvq31b
Empagliflozin in Patients with Chronic Kidney Disease | NEJM https://t.co/ZokDjvq31b
Really great thread on #EMPAKIDNEY by the trialists themselves! Congratulations @willkidney @RichardHaynes3 @Oxford_NDPH what a privilege to have learnt from all of you. Simpub @NEJM
Published https://www.nejm.org/doi/full/10.1056/NEJMoa2204233?query=featured_home #KidneyWk
Maybe the most anticipated? William Herrington, @willkidney, presenting EMPA-KIDNEY - published in the NEJM today #kidneywk https://www.nejm.org/doi/full/10.1056/NEJMoa2204233?query=featured_home
NEJM ruins the suspense by posting EMPAKidney manuscript early https://www.nejm.org/doi/full/10.1056/NEJMoa2204233?query=featured_home
リ
CJ
CH
SS